Equities analysts expect Accuray Incorporated (NASDAQ:ARAY) to announce sales of $90.10 million for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Accuray’s earnings, with the lowest sales estimate coming in at $88.10 million and the highest estimate coming in at $92.10 million. Accuray reported sales of $85.33 million in the same quarter last year, which indicates a positive year-over-year growth rate of 5.6%. The business is scheduled to announce its next earnings report on Thursday, November 4th.
According to Zacks, analysts expect that Accuray will report full-year sales of $417.85 million for the current year, with estimates ranging from $417.70 million to $418.00 million. For the next year, analysts expect that the business will report sales of $438.85 million, with estimates ranging from $434.70 million to $443.00 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow Accuray.
Accuray (NASDAQ:ARAY) last announced its earnings results on Tuesday, August 10th. The medical equipment provider reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.01. Accuray had a positive return on equity of 4.91% and a negative net margin of 1.59%. The business had revenue of $110.94 million during the quarter, compared to analysts’ expectations of $101.65 million. During the same quarter in the prior year, the firm earned ($0.01) earnings per share.
In other Accuray news, Director Joseph E. Whitters acquired 17,500 shares of the stock in a transaction that occurred on Monday, August 16th. The stock was bought at an average cost of $3.64 per share, for a total transaction of $63,700.00. Following the completion of the transaction, the director now owns 314,210 shares of the company’s stock, valued at approximately $1,143,724.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Joshua Levine acquired 15,000 shares of the stock in a transaction that occurred on Wednesday, August 18th. The stock was acquired at an average price of $3.63 per share, with a total value of $54,450.00. Following the completion of the transaction, the chief executive officer now directly owns 1,097,901 shares of the company’s stock, valued at approximately $3,985,380.63. The disclosure for this purchase can be found here. Insiders bought 42,500 shares of company stock valued at $154,650 over the last 90 days. Company insiders own 4.00% of the company’s stock.
A number of institutional investors have recently modified their holdings of ARAY. Capital Analysts LLC purchased a new position in shares of Accuray during the second quarter worth $27,000. Altshuler Shaham Ltd purchased a new position in shares of Accuray during the first quarter worth $38,000. Royal Bank of Canada boosted its position in shares of Accuray by 211.3% during the first quarter. Royal Bank of Canada now owns 8,983 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 6,097 shares during the period. Clear Creek Financial Management LLC purchased a new position in shares of Accuray during the second quarter worth $47,000. Finally, Tudor Investment Corp Et Al purchased a new position in shares of Accuray during the first quarter worth $54,000. Institutional investors own 79.04% of the company’s stock.
Shares of ARAY stock traded up $0.07 during trading hours on Wednesday, reaching $3.57. The company had a trading volume of 602,954 shares, compared to its average volume of 745,990. The company has a debt-to-equity ratio of 2.47, a quick ratio of 1.18 and a current ratio of 1.83. The stock has a fifty day moving average of $3.90 and a 200-day moving average of $4.44. The company has a market capitalization of $324.26 million, a price-to-earnings ratio of -51.00 and a beta of 1.86. Accuray has a 12-month low of $2.22 and a 12-month high of $6.01.
Accuray, Inc is a radiation oncology company. It engages in the development, manufacture and sale of treatment solutions that includes cyberKnife and tomo therapy systems, designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy and adaptive radiation therapy.
Featured Article: How to Invest in an Index Fund
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.